Previous reports of EpCAM expression in carcinomas of the head and neck district showed that EpCAM is overexpressed in approximately 22%–75% of oropharyngeal and larynx carcinomas, in 86% of squamous cell carcinomas of the cervical esophagus and in 83%–100% of salivary glands carcinomas with different immunostaining intensities [16]–[17]. Here, EPCAM is linked to carcinoma.